3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Active not recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
4
Renal Insufficiency
2
Paraproteinemias
2
Neoplasms, Plasma Cell
2
Neoplasms by Histologic Type
2
Neoplasms
2
Hematologic Diseases
2
Blood Protein Disorders
2
Monoclonal Gammopathy of Undetermined Significance
1
Immunoglobulin Light-chain Amyloidosis
1
Cryoglobulinemia, Familial Mixed
1
Amyloidosis
1
Interventions
Cyclophosphamide
4
Dexamethasone
3
sargramostim
2
Bortezomib
2
pomalidomide
1
isatuximab
1
elotuzumab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
auricularum
1
Thalidomide
1
Technetium Tc 99m Pyrophosphate
1
Technetium
1
Registries
1
Radiotherapy
1
Pharmacogenomic Testing
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Lenalidomide
1
Ketamine
1
Filgrastim
1
Carboplatin
1
Calcium Dobesilate
1
Amifostine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Immunoglobulin Light-chain Amyloidosis
×
isatuximab
×
Clear all
NCT05066607
2024-03-06
IsAMYP
Intergroupe Francophone du Myelome
Phase 2
Unknown
46 enrolled